Skip to main content

NCT00269854 - A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease

A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


CSR Summary

Not Yet Available


Data Specification

Not Yet Available


Annotated CRF

Not Yet Available

Product Info

Generic Name
Infliximab
Product Name
REMICADE®
Therapeutic Area
Digestive System Diseases
Enrollment
108
Product Class
Antirheumatic agents - biologic response modifiers
Sponsor Protocol Number
C0168T16
Data Holder
Johnson & Johnson
Condition Studied
Crohn's Disease

Supporting Documentation

Analysis Datasets
Collected Datasets
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.